-+ 0.00%
-+ 0.00%
-+ 0.00%

Shisi Pharmaceutical Group (02005): Ziprasidone hydrochloride was approved by the China National Drug Administration and registered as an API for use in marketed formulations

Zhitongcaijing·08/07/2026 09:09:04
Listen to the news

Zhitong Finance App News, Shisi Pharmaceutical Group (02005) announced that the Group's ziprasidone hydrochloride has been approved by the China National Drug Administration and registered as an active ingredient for use in marketed formulations. Ziprasidone hydrochloride is a novel atypical broad-spectrum antipsychotic. It is a second-generation antipsychotic drug, mainly used to treat schizophrenia.

This approval further enhances the Group's supporting capabilities for neuropsychiatric APIs and enriches the Group's highly active ingredient (HPAPI) product matrix.